Our Mission
Our Mission is to pioneer breakthrough therapies that transform the lives of patients and thier families affected by cancer and autoimmune diseases worldwide.
About TargaZyme
At TargaZyme, we develop transformative medicines and technologies by building agile, focused, capital efficient companies that we refer to as the Zymes. Targazyme was founded with the goal of developing and delivering medicines to patients safer and more efficently with greater efficacy.
We see ourselves as reinventing the concept of what a large pharma company of the future might look like. Instead of a single and centralized organization, we are building the ‘Google of Healthcare’ - a decentralized family of companies working to improve the process of developing and delivering medicines to patients. Each company in our ecosystem benefits from being a part of that broader family backed by TargaZyme. Each of TargaZyme’s technologies were founded by a world-renowned physician scientists.
TargaZyme is a pioneer of cellular therapy and has accumulated the experience of advancing a portfolio of companies and products, including a Phase 3 Special Protocol Assessment (SPA) award from the FDA, with multiple FDA orphan-drug designations. Targazyne has been awarded over 40 worldwide-awarded patents with another 35 patent applications pending.
TargaZyme has partnerships and collaborations with Kyowa Hakko Kirin, Aragen Bioscience, AVID Biotechnologies, and Thermo Fisher in addition to various medical research institutions, including MD Anderson Cancer Center, Oklahoma Medical Research Foundation, Harvard Medical Center, University of Pennsylvania Medical Center, Cleveland Clinic, Scripps Hospitals, Case Western/University Hospitals, Fred Hutchinson Cancer Research Center, Moore’s Cancer Center, UCSF,UCLA Medical Cancer Center, Northwestern University Medical Center, Sanford-Burnham Medical Research Institute and Indiana University.
Gheath Al-Atrash MD, PhD is the medical/scientific founder of TZ 102 T-cell therapy and is a physician-scientist at The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy.
Rodger McEver, MD is a world-renowned glycobiologist and hematologist who also serves as Oklahoma Medical Research Foundation’s Chief Scientific Officer. Dr. McEver also co-founded a pair of biotechnology companies: Selexys Pharmaceuticals Corp., which was acquired by Novartis, and Tetherex Pharmaceuticals.
Lijun Xia, MD, PhD has spent two decades studying O-glycans, a form of sugar that the body produces and that comprises nearly 80 percent of a thick mucous layer inside the colon and the gastrointestinal tract. Dr. Xia was a practicing hematologist/oncologist and currently chairs the Cardiovascular Department at the Oklahoma Medical Research Foundation (OMRF)
